Cargando…

Park EJ, Prajuabjinda O, Soe ZY, et al. Exosomal regulation of lymphocyte homing to the gut. Blood Adv. 2019;3(1):1-11.

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2019
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341185/ https://www.ncbi.nlm.nih.gov/pubmed/30642885 http://dx.doi.org/10.1182/bloodadvances.2019030965

Ejemplares similares

Park EJ, Prajuabjinda O, Soe ZY, et al. Exosomal regulation of lymphocyte homing to the gut. Blood Adv. 2019;3(1):1-11.
Publicado: (2019)

Lai C, Ranpura V, Wu C, et al. Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab. Blood Adv. 2019;3(7):980-983.
Publicado: (2019)

Manasanch EE, Han G, Mathur R, et al. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv. 2019;3(15):2400-2408.
Publicado: (2019)

Abraham AA, John TD, Keller MD, et al. Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients. Blood Adv. 2019;3(14):2057-2068.
Publicado: (2019)

Keleku-Lukwete N, Suzuki M, Panda H, et al. Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice. Blood Adv. 2019;3(8):1285-1297.
Publicado: (2019)

EjRAV1/2 Delay Flowering Through Transcriptional Repression of EjFTs and EjSOC1s in Loquat
por: Peng, Ze, et al.
Publicado: (2021)

Erratum to “A Primer on Magnetic Resonance-Guided Laser Interstitial Thermal Therapy for Medically Refractory Epilepsy” by Lee EJ, et al. (J Korean Neurosurg Soc 62 : 353-360, 2019)
Publicado: (2019)

EjBZR1 represses fruit enlargement by binding to the EjCYP90 promoter in loquat
por: Su, Wenbing, et al.
Publicado: (2021)

The Role of EjSPL3, EjSPL4, EjSPL5, and EjSPL9 in Regulating Flowering in Loquat (Eriobotrya japonica Lindl.)
por: Jiang, Yuanyuan, et al.
Publicado: (2019)

Gill S, Vides V, Frey NV, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022;6(21):5774-5785.
Publicado: (2023)

The Potential Adjuvanticity of CAvant(®)SOE for Foot-and-Mouth Disease Vaccine
por: Ahn, Young-Hoon, et al.
Publicado: (2021)

Palma-Barqueros V, Bury L, Kunishima S, et al. Expanding the genetic spectrum of TUBB1-related thrombocytopenia. Blood Adv. 2021;5(24):5453–5467.
Publicado: (2023)

Erratum: Cheng, Z.Y., et al. Casticin Induces DNA Damage and Affects DNA Repair Associated Protein Expression in Human Lung Cancer A549 Cells (Running Title: Casticin Induces DNA Damage in Lung Cancer Cells). Molecules 2020, 25, 341
por: Editorial Office, Molecules
Publicado: (2021)

Research on the Trajectory Model for ZY-3
por: Chen, Yifu, et al.
Publicado: (2014)

Tiong IS, Dillon R, Ivey A, et al. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Adv. 2021;5(23):5107-5111.
Publicado: (2022)

Visco C, Marcheselli L, Mina R, et al. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. Blood Adv. (2022);6(1):327-338.
Publicado: (2023)

Definition of Classes of Evidence (CoE) and Overall Strength of Evidence (SoE)
Publicado: (2014)

Definition of Levels of Evidence (LoE) and Overall Strength of Evidence (SoE)
Publicado: (2014)

Definition of levels of evidence (LoE) and overall strength of evidence (SoE)
Publicado: (2015)

Definition of levels of evidence (LoE) and overall strength of evidence (SoE)
Publicado: (2015)

Definition of Classes of Evidence (CoE) and Overall Strength of Evidence (SoE)
Publicado: (2013)

COVID-19 Pandemic and Corporate Liquidity: The Role of SOEs’ Trade Credit Response
por: Wang, Xun, et al.
Publicado: (2023)

Lisi V, Blanchard È, Vladovsky M, et al. Unified gene expression signature of novel NPM1 exon 5 mutations in acute myeloid leukemia. Blood Adv. 2022;6(17):5160-5164.
Publicado: (2023)

Gowin K, Ballen K, Ahn KW, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020;4(9):1965-1973.
Publicado: (2021)

Kudo K, Kubota Y, Toki T, et al. Childhood acute myeloid leukemia with 5q deletion and HNRNPH1-MLLT10 fusion: the first case report. Blood Adv. 2022;6(10):3162-3166.
Publicado: (2022)

Erratum to "Optimal Effect-Site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway Removal during Emergence" by Park SJ, et al.
Publicado: (2015)

Schuelke MR, Bassiri H, Behrens EM, et al. Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients. Blood Adv. 2023;7(18):5603–5607.
Publicado: (2023)

The Role of EjSOC1s in Flower Initiation in Eriobotrya japonica
por: Jiang, Yuanyuan, et al.
Publicado: (2019)

Antisynthetase syndrome with rare EJ‐1 antibodies with antiphospholipid syndrome
por: Chhor, Louis, et al.
Publicado: (2022)

Erratum to “Network Analysis of Language Disorganization in Patients with Schizophrenia” by Park SC, et al. (Yonsei Med J 2020; 61(8): 726-730.)
Publicado: (2020)

Big health data for elderly employees job performance of SOEs: visionary and enticing challenges
por: Zhang, Qian
Publicado: (2023)

Mulder DT, Mahé ER, Dowar M, et al. CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling. Blood Adv. 2018;2(23):3506-3514.
Publicado: (2019)

Miles J, Bailey SL, Obenaus AM, et al. Storage temperature determines platelet GPVI levels and function in mice and humans. Blood Adv. 2021;5(19):3839-3849.
Publicado: (2022)

Greenwood M, Trahair T, Sutton R, et al. An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL. Blood Adv. 2021;5(24):5574-5583.
Publicado: (2023)

Huynh A, Arnold DM, Michael JV, et al. Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S. Blood Adv. 2023;7(2):246-250.
Publicado: (2023)

Tam CS, Dimopoulos M, Garcia-Sanz R, et al. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv. 2022;6(4):1296-1308.
Publicado: (2022)

Fabrizio VA, Boelens JJ, Mauguen A, et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022;6(7):1961-1968.
Publicado: (2023)

Ilich A, Gernsheimer TB, Triulzi DJ, et al. Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. Blood Adv. 2023;7(6):900-908.
Publicado: (2023)

van Rhee F, Rosenthal A, Kanhai K, et al. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv. 2022;6(16):4773-4781.
Publicado: (2023)

Mazzara S, Travaini L, Botta F, et al. Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL. Blood Adv. 2023;7(4):630-643.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lofq01d4hml7ds61lp1mkjoi19